Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper
Source: Life Science Leader
By Ben Comer, Chief Editor, Life Science Leader
Beginning in 2008 as a Gothenburg, Sweden-based spin-out of AstraZeneca, Albireo Pharma was created on the founders’ — Jan Mattsson and Per-Göran Gillberg — expertise in novel bile acid modulators. In 2015, Albireo established an office in Boston and hired Ron Cooper as president and CEO. One year later, Albireo became a publicly traded company through a share exchange and merger with Biodel Inc., a Danbury, CT-based specialty pharmaceutical company.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more